SCHEMBL1245359

SCHEMBL1245359

Cc1cc(SCC=C(c2ccc(C#Cc3ccccc3)cc2)c2ccc(C#Cc3ccccc3)cc2)ccc1OCC(=O)O

nearest known ligand 0.74

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
PPARD Q03181 16/20 0.74
PPARA Q07869 2/20 0.69
FFAR1 O14842 3/20 0.45
PTGDR2 Q9Y5Y4 1/20 0.45
PPARG P37231 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1745624 0.99 PPARD (0.72) PPARDPPARAFFAR1PTGDR2
SCHEMBL1745627 0.99 PPARD (0.72) PPARDPPARAFFAR1PTGDR2
SCHEMBL1245503 0.91 PPARD (0.64) PPARDPPARAFFAR1PTGDR2PPARG
SCHEMBL1245382 0.89 PPARD (0.70) PPARDPPARA
SCHEMBL12891111 0.89 PPARD (0.64) PPARDPPARAFFAR1
SCHEMBL1245361 0.89 PPARD (0.64) PPARDPPARA
SCHEMBL1244061 0.88 PPARD (0.66) PPARDPPARA
SCHEMBL5959547 0.88 PPARD (0.78) PPARDPPARAPPARG
SCHEMBL5959504 0.88 PPARD (0.78) PPARDPPARAPPARG
SCHEMBL3270384 0.88 PPARD (0.78) PPARDPPARAPTGDR2PPARG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110039841-A1 Novel compounds, their preparation and use NOVO NORDISK A/S (DK) 2011-02-17 US claimed
EP-1763511-B1 PHENOXYACETIC ACID DERIVATIVES AS PPAR AGONISTS HIGH POINT PHARMACEUTICALS LLC (US) 2010-07-28 EP claimed
EP-1763511-A1 PHENOXYACETIC ACID DERIVATIVES AS PPAR AGONISTS NOVO NORDISK A/S (DK) 2007-03-21 EP claimed
WO-2005105735-A1 PHENOXYACETIC ACID DERIVATIVES AS PPAR AGONISTS NOVO NORDISK A/S (DK) 2005-11-10 WO claimed
US-20110039841-A1 Novel compounds, their preparation and use NOVO NORDISK A/S (DK) 2011-02-17 US disclosed
US-20110039841-A1 Novel compounds, their preparation and use NOVO NORDISK A/S (DK) 2011-02-17 US disclosed
EP-1763511-B1 PHENOXYACETIC ACID DERIVATIVES AS PPAR AGONISTS HIGH POINT PHARMACEUTICALS LLC (US) 2010-07-28 EP disclosed
EP-1763511-A1 PHENOXYACETIC ACID DERIVATIVES AS PPAR AGONISTS NOVO NORDISK A/S (DK) 2007-03-21 EP disclosed
WO-2005105735-A1 PHENOXYACETIC ACID DERIVATIVES AS PPAR AGONISTS NOVO NORDISK A/S (DK) 2005-11-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110039841-A1 Novel compounds, their preparation and use PPARG, PPARD, PPARA PPARD 2/4885PPARA 3/4885FFAR1 20/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.